We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Denosumab on MCF-7 Human Breast Cancer Cell Culture.
- Authors
BERİ, Emre; YENİGÜN, Vildan Betül; AKKAN, Ahmet Gökhan; TOLUK, Özlem
- Abstract
Introduction: One common condition encountered in patients receiving hormonal therapy for metastatic breast cancers and breast cancer is bone density loss. Denosumab is one of the bone resorption inhibitors used to prevent these adverse effects. In this study, we investigated the anticancer effects of denosumab on MCF-7 human breast cancer cell culture. Method: ER+ breast cancer cells (MCF-7) were used in this study to investigate the combination effect of progesterone and denosumab. The MTT cell viability test was used to calculate the half-maximal inhibitory concentrations (IC50) of both drugs and to observe cell viability after they were co-administered. To examine the cell growth rates and progression toward apoptosis, apoptosis analysis acridine orange/ethidium bromide (AO/EB), cell cycle analysis, and Ki-67 staining will be performed. Results: Cell viability results revealed that low doses of progesterone induced the proliferation of MCF-7 cells, while inducing cytotoxicity at higher doses (starting from 40 µM with an IC50 value of 82.4 µM, p<0.001). In addition, approximately 20 µM of denosumab caused half of the cells to die (p<0.001). When the non-toxic dose of progesterone (40 µM) was applied to the cells with several doses of denosumab, we did not observe any statistical difference in cell death. Two weeks following the initial test, at the second MTT test, cytotoxicity had decreased to 18%. When denosumab was administered alone, it caused nearly 25% of the MCF-7 cells to undergo apoptosis in the AO/EB analysis, whereas when administered together with progesterone, this rate decreased to 15%. Conclusion: The results showed that progesterone could counteract the cytotoxic and apoptotic effects of denosumab in MCF-7 cells, but more research is needed to confirm this result.
- Subjects
CANCER cell culture; DENOSUMAB; BREAST cancer; CELL cycle; CELL analysis; OSTEOCLASTS
- Publication
Bezmialem Science, 2024, Vol 13, pS6
- ISSN
2148-2373
- Publication type
Abstract